These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36199692)

  • 21. [Development and pharmacological effects of anti-RANKL monoclonal antibody drug denosumab].
    Takami M
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(3):162-9. PubMed ID: 23812074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
    Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
    J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skeletal and extraskeletal actions of denosumab.
    Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
    Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A bibliometric and visualization analysis of glucocorticoid-induced osteoporosis research from 2012 to 2021.
    Jiang B; Feng C; Li C; Tu C; Li Z
    Front Endocrinol (Lausanne); 2022; 13():961471. PubMed ID: 35992120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Denosumab treatment for fibrous dysplasia.
    Boyce AM; Chong WH; Yao J; Gafni RI; Kelly MH; Chamberlain CE; Bassim C; Cherman N; Ellsworth M; Kasa-Vubu JZ; Farley FA; Molinolo AA; Bhattacharyya N; Collins MT
    J Bone Miner Res; 2012 Jul; 27(7):1462-70. PubMed ID: 22431375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of bone metastases in refractory prostate cancer--role of denosumab.
    Paller CJ; Carducci MA; Philips GK
    Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
    Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
    J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.
    Cheng K; Zhang H; Guo Q; Zhai P; Zhou Y; Yang W; Wang Y; Lu Y; Shen Z; Wu H
    Front Immunol; 2022; 13():975695. PubMed ID: 36148235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Trends and Research Hotspots in Pancreatic Stellate Cells: A Bibliometric Study.
    Yang Z; Xie Z; Wan J; Yi B; Xu T; Shu X; Zhao Z; Tang C
    Front Oncol; 2022; 12():896679. PubMed ID: 35719926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases.
    Yasuda H
    World J Orthop; 2013 Oct; 4(4):207-17. PubMed ID: 24147256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New anti-resorptives and antibody mediated anti-resorptive therapy.
    Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
    Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bibliometric analysis of global research trends on male osteoporosis: a neglected field deserves more attention.
    Wu H; Sun Z; Tong L; Wang Y; Yan H; Sun Z
    Arch Osteoporos; 2021 Oct; 16(1):154. PubMed ID: 34632530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical professionalism research characteristics and hotspots: a 10-year bibliometric analysis of publications from 2010 to 2019.
    Song X; Jiang N; Li H; Ding N; Wen D
    Scientometrics; 2021; 126(9):8009-8027. PubMed ID: 34248230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research Hotspots and Trends of Peripheral Nerve Injuries Based on Web of Science From 2017 to 2021: A Bibliometric Analysis.
    Zhang S; Huang M; Zhi J; Wu S; Wang Y; Pei F
    Front Neurol; 2022; 13():872261. PubMed ID: 35669875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab for the treatment of osteoporosis.
    Iqbal J; Sun L; Zaidi M
    Curr Osteoporos Rep; 2010 Dec; 8(4):163-7. PubMed ID: 20857349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of research trends concerning application of stent implantation in the treatment of pancreatic diseases by quantitative and biclustering analysis: a bibliometric analysis.
    Zhu X; Niu X; Li T; Liu C; Chen L; Tan G
    PeerJ; 2019; 7():e7674. PubMed ID: 31660258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.